Dianthus Therapeutics (DNTH) Financials

$17.85 +0.17 (+0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$17.84 -0.01 (-0.03%)

As of 07:24 PM Eastern

Annual Income Statements for Dianthus Therapeutics

This table shows Dianthus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-85	-44	-28
Consolidated Net Income / (Loss)	-85	-44	-28
Net Income / (Loss) Continuing Operations	-85	-44	-28
Total Pre-Tax Income	-85	-44	-28
Total Operating Income	-102	-48	-30
Total Gross Profit	6.24	2.83	6.42
Total Revenue	6.24	2.83	6.42
Operating Revenue	6.24	2.83	6.42
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	108	51	36
Selling, General & Admin Expense	25	18	6.74
Research & Development Expense	83	33	29
Total Other Income / (Expense), net	17	4.62	1.23
Interest & Investment Income	17	4.76	1.15
Other Income / (Expense), net	-0.47	-0.15	0.08
Basic Earnings per Share	($2.55)	($8.45)	($32.57)
Weighted Average Basic Shares Outstanding	33.31M	5.15M	874.23K
Diluted Earnings per Share	($2.55)	($8.45)	($32.57)
Weighted Average Diluted Shares Outstanding	33.31M	5.15M	874.23K
Weighted Average Basic & Diluted Shares Outstanding	32.13M	29.35M	60.64M
Cash Dividends to Common per Share	$0.00	$0.00	-

This table shows Dianthus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-28	-25	-18	-14	-11	-15	-11	-7.09	20	-7.78
Consolidated Net Income / (Loss)	-28	-25	-18	-14	-11	-15	-11	-7.09	20	-7.78
Net Income / (Loss) Continuing Operations	-28	-25	-18	-14	-11	-15	-11	-7.09	20	-7.78
Total Pre-Tax Income	-28	-25	-18	-14	-11	-15	-11	-7.09	20	-7.78
Total Operating Income	-32	-30	-22	-18	-13	-16	-12	-7.68	20	-8.25
Total Gross Profit	1.33	2.17	1.86	0.87	0.46	0.92	0.97	0.48	5.24	1.17
Total Revenue	1.33	2.17	1.86	0.87	0.46	0.92	0.97	0.48	5.24	1.17
Operating Revenue	1.33	2.17	1.86	0.87	0.46	0.92	0.97	0.48	-	1.17
Total Operating Expenses	33	32	24	19	13	17	13	8.16	-15	9.43
Selling, General & Admin Expense	6.83	6.53	6.00	5.64	4.63	8.72	2.49	2.31	-9.23	2.21
Research & Development Expense	26	26	18	13	8.78	7.96	10	5.85	-5.99	7.22
Total Other Income / (Expense), net	3.48	4.73	4.60	4.10	2.39	1.00	0.64	0.59	-0.94	0.47
Interest & Investment Income	3.99	4.45	4.71	4.22	2.44	1.03	0.69	0.61	-0.97	0.42
Other Income / (Expense), net	-0.51	0.28	-0.11	-0.13	-0.05	-0.03	-0.05	-0.01	-	0.05
Basic Earnings per Share	($0.76)	($0.74)	($0.51)	($0.54)	$16.16	($3.78)	($12.73)	($8.10)	($22.99)	($8.90)
Weighted Average Basic Shares Outstanding	33.31M	34.24M	34.23M	25.67M	5.15M	3.91M	874.90K	874.71K	874.23K	874.33K
Diluted Earnings per Share	($0.76)	($0.74)	($0.51)	($0.54)	$16.16	($3.78)	($12.73)	($8.10)	($22.99)	($8.90)
Weighted Average Diluted Shares Outstanding	33.31M	34.24M	34.23M	25.67M	5.15M	3.91M	874.90K	874.71K	874.23K	874.33K
Weighted Average Basic & Diluted Shares Outstanding	32.13M	29.60M	29.35M	29.35M	29.35M	14.82M	60.66M	60.65M	60.64M	-

This table details how cash moves in and out of Dianthus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-109	117	7.79
Net Cash From Operating Activities	-78	-37	-29
Net Cash From Continuing Operating Activities	-78	-37	-29
Net Income / (Loss) Continuing Operations	-85	-44	-28
Consolidated Net Income / (Loss)	-85	-44	-28
Depreciation Expense	0.10	0.07	0.03
Amortization Expense	-5.70	-1.14	-0.49
Non-Cash Adjustments To Reconcile Net Income	13	3.65	1.59
Changes in Operating Assets and Liabilities, net	-0.54	4.11	-1.72
Net Cash From Investing Activities	-287	20	-60
Net Cash From Continuing Investing Activities	-287	20	-60
Purchase of Property, Plant & Equipment	-0.11	-0.11	-0.14
Purchase of Investments	-414	-57	-62
Sale and/or Maturity of Investments	127	78	2.00
Net Cash From Financing Activities	256	134	97
Net Cash From Continuing Financing Activities	256	134	97
Repayment of Debt	0.00	-0.38	0.00
Issuance of Debt	0.00	0.38	0.00
Issuance of Common Equity	25	0.00	-
Other Financing Activities, net	231	134	0.00
Cash Interest Paid	0.00	0.00	0.00
Cash Income Taxes Paid	0.00	0.00	0.00

This table details how cash moves in and out of Dianthus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-11	-280	-16	197	-25	117	17	7.85	-22	106
Net Cash From Operating Activities	-27	-21	-15	-15	-12	-9.99	-4.73	-10	-8.85	16
Net Cash From Continuing Operating Activities	-27	-21	-15	-15	-12	-9.99	-4.73	-10	-8.85	17
Net Income / (Loss) Continuing Operations	-28	-25	-18	-14	-11	-15	-11	-7.09	-10	22
Consolidated Net Income / (Loss)	-28	-25	-18	-14	-11	-15	-11	-7.09	-10	22
Depreciation Expense	0.03	0.03	0.02	0.02	0.02	0.02	0.01	0.01	0.01	-0.97
Amortization Expense	-2.69	-2.25	-0.33	-0.43	-0.44	-0.26	-0.14	-0.29	-0.36	-
Non-Cash Adjustments To Reconcile Net Income	5.37	3.08	2.71	1.78	1.06	1.08	0.61	0.91	2.51	-6.09
Changes in Operating Assets and Liabilities, net	-1.72	3.06	0.68	-2.56	-1.93	3.94	5.93	-3.83	-0.89	1.93
Net Cash From Investing Activities	-23	-259	1.17	-5.51	-8.24	-12	22	18	-13	-6.88
Net Cash From Continuing Investing Activities	-23	-259	1.17	-5.51	-8.24	-12	22	18	-13	-6.88
Purchase of Property, Plant & Equipment	-0.03	-0.03	-0.02	-0.03	-0.01	-0.07	-0.02	-0.01	-0.03	0.05
Purchase of Investments	-108	-278	-6.81	-20	-26	-27	-	-3.86	-15	-6.93
Sale and/or Maturity of Investments	85	19	8.00	15	18	16	22	22	2.00	-
Net Cash From Financing Activities	40	0.30	-2.20	218	-4.87	138	-	0.00	-	97
Net Cash From Continuing Financing Activities	40	0.30	-2.20	218	-4.87	138	-	0.00	-	97
Other Financing Activities, net	0.48	0.30	0.05	230	-4.87	138	-	0.00	-	-

This table presents Dianthus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	374	179	83
Total Current Assets	281	177	82
Cash & Equivalents	23	132	15
Short-Term Investments	252	41	60
Accounts Receivable	0.81	0.29	4.70
Prepaid Expenses	4.86	3.26	0.91
Other Current Assets	0.00	0.18	0.94
Plant, Property, & Equipment, net	0.19	0.19	0.14
Total Noncurrent Assets	93	1.77	0.94
Long-Term Investments	82	0.00	-
Other Noncurrent Operating Assets	11	1.77	0.94
Total Liabilities & Shareholders' Equity	374	179	83
Total Liabilities	22	11	9.45
Total Current Liabilities	18	9.63	8.23
Accounts Payable	4.58	2.61	1.17
Accrued Expenses	13	6.50	6.61
Current Deferred Revenue	0.48	0.10	0.10
Other Current Liabilities	0.32	0.42	0.35
Total Noncurrent Liabilities	3.08	0.90	1.23
Noncurrent Deferred Revenue	1.91	0.74	0.79
Other Noncurrent Operating Liabilities	1.17	0.17	0.44
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	0.00	118
Total Equity & Noncontrolling Interests	352	169	-44
Total Preferred & Common Equity	352	169	-44
Preferred Stock	0.00	0.00	0.00
Total Common Equity	352	169	-44
Common Stock	527	258	1.66
Retained Earnings	-174	-89	-46
Accumulated Other Comprehensive Income / (Loss)	0.11	0.05	-0.16

This table presents Dianthus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023
Total Assets	354	369	382	192	79	83
Total Current Assets	287	366	381	191	79	83
Cash & Equivalents	34	314	330	157	63	49
Short-Term Investments	247	47	47	33	15	30
Accounts Receivable	1.39	0.84	0.44	0.75	-	-
Prepaid Expenses	3.68	3.31	3.01	0.83	1.05	2.91
Other Current Assets	1.29	0.84	0.44	-	-	-
Plant, Property, & Equipment, net	0.19	0.19	0.20	0.20	0.00	0.00
Total Noncurrent Assets	67	3.08	1.34	0.81	0.00	0.00
Long-Term Investments	61	-	-	-	-	-
Other Noncurrent Operating Assets	5.09	3.08	1.34	0.81	0.00	0.00
Total Liabilities & Shareholders' Equity	354	369	382	192	79	83
Total Liabilities	16	11	9.78	14	4.03	5.98
Total Current Liabilities	16	10	8.96	13	4.03	5.98
Accounts Payable	7.57	3.70	2.61	1.37	0.81	1.08
Accrued Expenses	7.73	5.86	5.85	11	3.22	4.90
Current Deferred Revenue	0.10	0.10	0.10	0.10	-	-
Other Current Liabilities	0.31	0.38	0.40	0.41	0.00	0.00
Total Noncurrent Liabilities	0.64	0.71	0.82	1.00	0.00	0.00
Noncurrent Deferred Revenue	0.64	0.68	0.72	0.75	-	-
Other Noncurrent Operating Liabilities	0.00	0.03	0.10	0.26	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	338	358	373	178	75	77
Total Preferred & Common Equity	338	358	373	178	75	77
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	338	358	373	178	75	77
Common Stock	483	479	476	257	509	509
Retained Earnings	-146	-121	-103	-79	-434	-431
Accumulated Other Comprehensive Income / (Loss)	0.68	-0.04	-0.03	-0.00	-0.00	-0.02

This table displays calculated financial ratios and metrics derived from Dianthus Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	120.63%	-55.96%	0.00%
EBITDA Growth	-118.56%	-64.19%	58.61%
EBIT Growth	-111.79%	-63.12%	60.34%
NOPAT Growth	-111.45%	-62.17%	60.23%
Net Income Growth	-95.08%	-52.95%	59.97%
EPS Growth	69.82%	74.06%	-2,424.81%
Operating Cash Flow Growth	-112.09%	-26.80%	51.17%
Free Cash Flow Firm Growth	-133.36%	-32.28%	56.17%
Invested Capital Growth	7.34%	-164.34%	56.89%
Revenue Q/Q Growth	16.19%	-62.88%	0.00%
EBITDA Q/Q Growth	-25.10%	-213.59%	0.00%
EBIT Q/Q Growth	-23.43%	-227.54%	0.00%
NOPAT Q/Q Growth	-22.87%	-226.56%	0.00%
Net Income Q/Q Growth	-26.65%	-223.52%	0.00%
EPS Q/Q Growth	-117.75%	82.25%	0.00%
Operating Cash Flow Q/Q Growth	-24.91%	-8.87%	0.00%
Free Cash Flow Firm Q/Q Growth	-10.56%	-2,741.30%	-692.81%
Invested Capital Q/Q Growth	4.57%	57.80%	0.00%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-1,731.19%	-1,747.59%	-468.75%
Operating Margin	-1,633.75%	-1,704.67%	-462.91%
EBIT Margin	-1,641.28%	-1,709.80%	-461.60%
Profit (Net Income) Margin	-1,362.77%	-1,541.22%	-443.76%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	83.03%	90.14%	96.13%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-32.60%	-35.92%	-23.12%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-36.98%	-36.81%	-21.70%
Return on Assets (ROA)	-30.71%	-33.18%	-20.86%
Return on Common Equity (ROCE)	-32.60%	-18.44%	-12.04%
Return on Equity Simple (ROE_SIMPLE)	-24.11%	-25.79%	64.18%
Net Operating Profit after Tax (NOPAT)	-71	-34	-21
NOPAT Margin	-1,143.62%	-1,193.27%	-324.04%
Net Nonoperating Expense Percent (NNEP)	-5.15%	-7.89%	-6.09%
Return On Investment Capital (ROIC_SIMPLE)	-20.23%	-19.97%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	400.87%	642.57%	105.08%
R&D to Revenue	1,332.88%	1,162.10%	457.83%
Operating Expenses to Revenue	1,733.75%	1,804.67%	562.91%
Earnings before Interest and Taxes (EBIT)	-102	-48	-30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-108	-49	-30
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.83	0.91	0.00
Price to Tangible Book Value (P/TBV)	1.83	0.91	0.00
Price to Revenue (P/Rev)	103.48	54.53	3.63
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	46.23	0.00	10.25
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.02	-1.03	-1.02
Leverage Ratio	1.06	1.08	1.11
Compound Leverage Factor	0.88	0.98	1.07
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	160.24%
Common Equity to Total Capital	100.00%	100.00%	-60.24%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	17.28	8.33	0.67
Noncontrolling Interest Sharing Ratio	0.00%	48.66%	47.91%
Liquidity Ratios	-	-	-
Current Ratio	15.22	18.43	9.97
Quick Ratio	14.96	18.07	9.75
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-72	-31	-23
Operating Cash Flow to CapEx	-74,457.14%	-33,510.00%	-20,913.67%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.02	0.02	0.05
Accounts Receivable Turnover	11.33	1.13	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	32.90	17.28	1.69
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	32.23	322.51	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	32.23	322.51	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-4.49	-4.85	-1.83
Invested Capital Turnover	-1.34	-0.85	-2.11
Increase / (Decrease) in Invested Capital	0.36	-3.01	2.42
Enterprise Value (EV)	288	-20	66
Market Capitalization	645	154	23
Book Value per Share	$11.91	$11.40	($50.75)
Tangible Book Value per Share	$11.91	$11.40	($50.75)
Total Capital	352	169	74
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-357	-174	-75
Capital Expenditures (CapEx)	0.11	0.11	0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-13	-5.90	-1.68
Debt-free Net Working Capital (DFNWC)	262	168	74
Net Working Capital (NWC)	262	168	74
Net Nonoperating Expense (NNE)	14	9.83	7.68
Net Nonoperating Obligations (NNO)	-357	-174	-75
Total Depreciation and Amortization (D&A)	-5.61	-1.07	-0.46
Debt-free, Cash-free Net Working Capital to Revenue	-205.12%	-208.70%	-26.21%
Debt-free Net Working Capital to Revenue	4,209.33%	5,938.43%	1,150.19%
Net Working Capital to Revenue	4,209.33%	5,938.43%	1,150.19%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.55)	($8.45)	($1.29)
Adjusted Weighted Average Basic Shares Outstanding	33.31M	5.15M	59.37M
Adjusted Diluted Earnings per Share	($2.55)	($8.45)	($1.29)
Adjusted Weighted Average Diluted Shares Outstanding	33.31M	5.15M	59.37M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.13M	29.35M	60.64M
Normalized Net Operating Profit after Tax (NOPAT)	-71	-34	-21
Normalized NOPAT Margin	-1,143.62%	-1,193.27%	-324.04%
Pre Tax Income Margin	-1,362.77%	-1,541.22%	-443.76%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Dianthus Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	190.15%	135.06%	92.26%	83.61%	-91.29%	-21.23%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-161.25%	-98.62%	-89.32%	-130.57%	-166.78%	-74.86%	32.12%	65.82%	0.00%	47.67%
EBIT Growth	-149.33%	-87.58%	-88.68%	-133.53%	-163.55%	-92.56%	34.60%	67.71%	0.00%	55.06%
NOPAT Growth	-146.34%	-89.73%	-88.55%	-132.25%	-144.31%	-90.93%	34.88%	67.76%	0.00%	54.76%
Net Income Growth	-169.24%	-70.52%	-58.05%	-93.93%	-154.09%	-89.66%	35.50%	69.11%	0.00%	0.00%
EPS Growth	-104.70%	80.42%	95.99%	93.33%	170.29%	57.53%	-4,289.66%	-1,976.92%	0.00%	0.00%
Operating Cash Flow Growth	-131.52%	-112.84%	-207.08%	-45.28%	-33.93%	-161.02%	71.93%	47.91%	0.00%	216.41%
Free Cash Flow Firm Growth	-274.84%	-6,154.62%	-78.23%	-45.09%	-133.55%	105.26%	34.89%	46.70%	2,773.48%	33.08%
Invested Capital Growth	7.34%	59.03%	16.73%	-41.75%	-164.34%	0.00%	20.23%	43.35%	56.89%	100.00%
Revenue Q/Q Growth	-38.95%	16.59%	113.16%	91.25%	-50.54%	-4.64%	103.57%	-90.92%	347.06%	0.00%
EBITDA Q/Q Growth	-10.19%	-40.74%	-23.09%	-36.86%	16.23%	-34.16%	-49.91%	-139.64%	319.36%	47.92%
EBIT Q/Q Growth	-9.49%	-32.73%	-24.18%	-38.16%	17.63%	-33.51%	-53.70%	-137.60%	349.59%	54.65%
NOPAT Q/Q Growth	-6.74%	-34.66%	-24.43%	-37.73%	17.79%	-33.82%	-53.27%	-126.28%	454.22%	54.35%
Net Income Q/Q Growth	-12.97%	-42.98%	-28.07%	-30.15%	28.45%	-32.52%	-57.14%	-136.30%	350.89%	54.93%
EPS Q/Q Growth	-2.70%	-45.10%	5.56%	-103.34%	527.51%	70.31%	-57.16%	64.77%	-158.31%	-2,968.97%
Operating Cash Flow Q/Q Growth	-29.05%	-46.39%	2.76%	-26.04%	-18.63%	-111.20%	54.00%	-16.19%	-154.05%	197.16%
Free Cash Flow Firm Q/Q Growth	18.10%	-72.74%	-43.11%	-85.13%	-1,422.96%	105.08%	-16.50%	-142.81%	307.29%	37.02%
Invested Capital Q/Q Growth	4.57%	-89.11%	42.77%	10.29%	57.80%	-284.38%	2.58%	-67.28%	0.00%	100.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-2,646.23%	-1,466.11%	-1,214.49%	-2,103.09%	-2,938.95%	-1,735.17%	-1,233.33%	-1,674.79%	383.54%	-781.67%
Operating Margin	-2,406.94%	-1,376.61%	-1,191.84%	-2,041.65%	-2,835.01%	-1,705.52%	-1,215.27%	-1,614.08%	390.27%	-703.67%
EBIT Margin	-2,445.70%	-1,363.67%	-1,197.80%	-2,056.06%	-2,846.17%	-1,708.87%	-1,220.54%	-1,616.60%	390.27%	-699.06%
Profit (Net Income) Margin	-2,144.80%	-1,159.02%	-945.09%	-1,573.00%	-2,311.38%	-1,597.73%	-1,149.64%	-1,489.29%	372.41%	-663.60%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	87.70%	84.99%	78.90%	76.51%	81.21%	93.50%	94.19%	92.12%	95.42%	94.93%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-32.60%	-25.99%	-26.19%	-22.31%	-35.92%	-15.09%	-6.17%	-11.03%	-23.12%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-55.11%	-26.77%	-22.04%	-28.46%	-61.28%	-135.19%	-75.63%	-80.22%	18.34%	0.00%
Return on Assets (ROA)	-48.33%	-22.75%	-17.39%	-21.77%	-49.76%	-126.40%	-71.24%	-73.90%	17.50%	0.00%
Return on Common Equity (ROCE)	-32.60%	-25.99%	-26.19%	-22.31%	-18.44%	-15.09%	-6.17%	-11.03%	-12.04%	0.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-19.86%	-15.82%	-13.47%	0.00%	-7.55%	-8.69%	-16.29%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-22	-21	-16	-12	-9.07	-11	-8.24	-5.38	20	-5.78
NOPAT Margin	-1,684.86%	-963.63%	-834.29%	-1,429.15%	-1,984.51%	-1,193.86%	-850.69%	-1,129.85%	390.27%	-492.57%
Net Nonoperating Expense Percent (NNEP)	-2.30%	-1.59%	-0.94%	-0.55%	-1.20%	-3.93%	-2.67%	-1.44%	-0.74%	-2.08%
Return On Investment Capital (ROIC_SIMPLE)	-6.34%	-	-	-	-5.37%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	515.01%	300.55%	321.90%	645.31%	1,013.57%	944.05%	257.17%	485.71%	-176.07%	188.32%
R&D to Revenue	1,991.93%	1,176.06%	969.94%	1,496.34%	1,921.44%	861.47%	1,058.10%	1,228.36%	-114.21%	615.35%
Operating Expenses to Revenue	2,506.94%	1,476.61%	1,291.84%	2,141.65%	2,935.01%	1,805.52%	1,315.27%	1,714.08%	-290.27%	803.67%
Earnings before Interest and Taxes (EBIT)	-32	-30	-22	-18	-13	-16	-12	-7.70	20	-8.20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-35	-32	-23	-18	-13	-16	-12	-7.97	20	-9.17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.83	2.38	2.12	2.36	0.91	4.65	0.62	0.62	0.00	0.00
Price to Tangible Book Value (P/TBV)	1.83	2.38	2.12	2.36	0.91	4.65	0.62	0.62	0.00	0.00
Price to Revenue (P/Rev)	103.48	149.78	184.45	273.08	54.53	108.93	5.85	6.99	3.63	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	46.23	85.93	96.86	156.13	0.00	83.99	0.00	0.00	10.25	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	549.99	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.02	-1.03	-1.01	-1.02	-1.03	-1.06	-1.03	-1.04	-1.02	-1.02
Leverage Ratio	1.06	1.06	1.03	1.04	1.08	1.08	1.21	1.22	1.11	1.09
Compound Leverage Factor	0.93	0.90	0.82	0.79	0.88	1.01	1.14	1.12	1.06	1.03
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	160.24%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-60.24%	0.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	17.90	29.58	42.94	54.68	8.98	35.64	-0.16	-1.51	2.66	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	48.66%	0.00%	0.00%	0.00%	47.91%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	15.22	18.30	36.46	42.52	18.43	14.64	19.49	13.95	9.97	0.00
Quick Ratio	14.96	17.98	36.05	42.13	18.07	14.57	19.23	13.07	9.75	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-23	-28	-16	-11	-6.06	0.46	-9.00	-7.73	18	-8.71
Operating Cash Flow to CapEx	-88,529.03%	-85,068.00%	-85,458.82%	-46,690.63%	-118,540.00%	-15,372.31%	-22,528.57%	-73,457.14%	-30,520.69%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.02	0.02	0.01	0.02	0.08	0.06	0.05	0.05	0.00
Accounts Receivable Turnover	11.33	5.01	0.00	0.00	1.13	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	32.90	27.95	0.00	0.00	17.28	0.00	0.00	0.00	1.69	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	32.23	72.82	0.00	0.00	322.51	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	32.23	72.82	0.00	0.00	322.51	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-4.49	-4.71	-2.49	-4.35	-4.85	-11	-2.99	-3.07	-1.83	0.00
Invested Capital Turnover	-1.34	-0.66	-1.50	-0.87	-0.85	-1.33	-2.33	-1.62	-2.11	0.00
Increase / (Decrease) in Invested Capital	0.36	6.78	0.50	-1.28	-3.01	-11	0.76	2.35	2.42	2.93
Enterprise Value (EV)	288	461	399	503	-20	639	-32	-32	66	83
Market Capitalization	645	804	760	880	154	829	46	48	23	83
Book Value per Share	$11.91	$11.51	$12.21	$12.70	$11.40	$2.94	$1.23	$1.28	($50.75)	$0.00
Tangible Book Value per Share	$11.91	$11.51	$12.21	$12.70	$11.40	$2.94	$1.23	$1.28	($50.75)	$0.00
Total Capital	352	338	358	373	169	178	75	77	74	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-357	-343	-361	-377	-174	-190	-78	-80	-75	0.00
Capital Expenditures (CapEx)	0.03	0.03	0.02	0.03	0.01	0.07	0.02	0.01	0.03	-0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-13	-9.34	-5.05	-5.07	-5.90	-11	-2.99	-2.53	-1.68	0.00
Debt-free Net Working Capital (DFNWC)	262	272	356	372	168	178	75	77	74	0.00
Net Working Capital (NWC)	262	272	356	372	168	178	75	77	74	0.00
Net Nonoperating Expense (NNE)	6.10	4.24	2.06	1.26	1.49	3.73	2.90	1.71	0.94	2.01
Net Nonoperating Obligations (NNO)	-357	-343	-361	-377	-174	-190	-78	-81	-75	0.00
Total Depreciation and Amortization (D&A)	-2.66	-2.23	-0.31	-0.41	-0.42	-0.24	-0.12	-0.28	-0.35	-0.97
Debt-free, Cash-free Net Working Capital to Revenue	-205.12%	-174.13%	-122.61%	-157.23%	-208.70%	-151.00%	-38.02%	-36.66%	-26.21%	0.00%
Debt-free Net Working Capital to Revenue	4,209.33%	5,064.83%	8,636.67%	11,537.44%	5,938.43%	2,343.02%	948.92%	1,123.73%	1,150.19%	0.00%
Net Working Capital to Revenue	4,209.33%	5,064.83%	8,636.67%	11,537.44%	5,938.43%	2,343.02%	948.92%	1,123.73%	1,150.19%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.76)	($0.74)	($0.51)	($0.54)	$16.16	($3.78)	($0.05)	($0.48)	($22.99)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	33.31M	34.24M	34.23M	25.67M	5.15M	3.91M	60.65M	60.65M	874.23K	0.00
Adjusted Diluted Earnings per Share	($0.76)	($0.74)	($0.51)	($0.54)	$16.16	($3.78)	($0.05)	($0.48)	($22.99)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	33.31M	34.24M	34.23M	25.67M	5.15M	3.91M	60.65M	60.65M	874.23K	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.13M	29.60M	29.35M	29.35M	29.35M	14.82M	60.66M	60.65M	60.64M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-22	-21	-16	-12	-9.07	-11	-8.24	-5.38	14	-5.78
Normalized NOPAT Margin	-1,684.86%	-963.63%	-834.29%	-1,429.15%	-1,984.51%	-1,193.86%	-850.69%	-1,129.85%	273.19%	-492.57%
Pre Tax Income Margin	-2,144.80%	-1,159.02%	-945.09%	-1,573.00%	-2,311.38%	-1,597.73%	-1,149.64%	-1,489.29%	372.41%	-663.60%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Dianthus Therapeutics' Financials

When does Dianthus Therapeutics's financial year end?

According to the most recent income statement we have on file, Dianthus Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Dianthus Therapeutics' net income changed over the last 2 years?

Dianthus Therapeutics' net income appears to be on an upward trend, with a most recent value of -$84.97 million in 2024, rising from -$28.48 million in 2022. The previous period was -$43.56 million in 2023. Find out what analysts predict for Dianthus Therapeutics in the coming months.

What is Dianthus Therapeutics's operating income?

Dianthus Therapeutics's total operating income in 2024 was -$101.86 million, based on the following breakdown:

Total Gross Profit: $6.24 million
Total Operating Expenses: $108.10 million

How has Dianthus Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Dianthus Therapeutics' total revenue changed from $6.42 million in 2022 to $6.24 million in 2024, a change of -2.8%.

How much debt does Dianthus Therapeutics have?

Dianthus Therapeutics' total liabilities were at $21.53 million at the end of 2024, a 104.4% increase from 2023, and a 127.7% increase since 2022.

How much cash does Dianthus Therapeutics have?

In the past 2 years, Dianthus Therapeutics' cash and equivalents has ranged from $15.37 million in 2022 to $132.33 million in 2023, and is currently $22.79 million as of their latest financial filing in 2024.

How has Dianthus Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Dianthus Therapeutics' book value per share changed from -50.75 in 2022 to 11.91 in 2024, a change of -123.5%.

Related Companies

This page (NASDAQ:DNTH) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dianthus Therapeutics (DNTH) Financials

Frequently Asked Questions About Dianthus Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dianthus Therapeutics (DNTH) Financials

Annual Income Statements for Dianthus Therapeutics

Quarterly Income Statements for Dianthus Therapeutics

Annual Cash Flow Statements for Dianthus Therapeutics

Quarterly Cash Flow Statements for Dianthus Therapeutics

Annual Balance Sheets for Dianthus Therapeutics

Quarterly Balance Sheets for Dianthus Therapeutics

Annual Metrics And Ratios for Dianthus Therapeutics

Quarterly Metrics And Ratios for Dianthus Therapeutics

Frequently Asked Questions About Dianthus Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools